Abstract:Objective To study the clinical characteristics of patients with myelodysplastic syndromes(MDS).Methods Thirty cases with MDS were analyzed retrospectively.Results(1) There were four cases with refractory anemia(RA),ten cases with refratctory cytopenia with multilineage dysplasia(RCMD),14 cases with refractory anemia with excess of blasts(MDS-RAEB) in which six cases developed into acute monocytic leukemia(AML-M5).(2) After androgen,ATRA,and Chinese medicine(Fufang Zao-fanwan) were used in six cases with MDS-RA,partial remission in one of them,hematological improvement in two of them,non-responses in three of them.(3) Five cases with MDS-RCMD combined with autoimmune diseases achieved hematological improvement after treated with low-dose Predisone(10～15 mg/d) as well as above three drugs.One case with MDS-RCMD achieved complete remission after being treated with Cyclosporine A 5 mg/kg in half an year.(4) One case with MDS-RAEB combined with hypoplasic red cell developed AML-M5 after being treated with Cyclosporine A in three months.Six cases with MDS-RAEB developed AML-M5 in half an year.Three of them gave up treatment and died of pneumonia at last.Two of them achieved non-response after being treated with two course of DA(idarubicin and cytrarabine) regimen,and died of pneumonia.One of them achieved partial remission after being treated with CAG(cytrarabine,aclarubicin and granulocyte colony-stimulating factor) regimen.Conclusion(1) MDS comprises a spectrum of heterogeneous,clonal disorder of hematopoiesis.20% cases of this study finally developed AML-M5.They have low response to chemotherapy and high fitality.Majority of them died of pneumonia.(2) MDS-RCMD combined with autoimmune diseases treated with low-dose Predisone as well as other drugs is improved to have curative effects.(3) Complete remission of patients with low-risk MDS treated with Cyclosporine A suggests that abnormal immune mechanism plays an important role in low-risk MDS patients.

Advances of Immunologic Therapy for Myelodysplastic Syndromes

Clinical application status and prospect of hypomethylating agents in treatment of myelodysplastic syndromes

Research Advancs of Hematopoietic Microenvironment for Myelodysplastic Syndromes——Reviews

Research advance of hematopoietic microenvironment for myelodysplastic syndromes]

Research Status on Immune Checkpoint Inhibitors in Treatment of Myelodysplastic Syndrome

Laboratory Study and Clinical Features of Hypoplastic Myelodysplastic Syndrome

Recent advances in myelodysplastic syndromes

The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome

[Recent Advances of Molecular Mechanisms Influencing Prognosis of Myelodysplastic Syndrome - Review].

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

[Research Progress on Gene Expression Abnormality of Hematopoietic Stem/Progenitor Cells in Myelodysplastic Syndromes].

Hematopoietic Stem Cell Transplantation in the Management of Myelodysplastic Syndrome: A Retrospective, Current, and Future Perspective

Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes

[Research Progress in MDS Mouse Model- Review].

Clinical analysis for thirty patients with myelodysplastic syndromes

[Updated treatment strategies for myelodysplastic syndromes]

Cellular and immunotherapies for myelodysplastic syndromes

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification

The immunobiology of myelodysplastic neoplasms: a mini-review

CLINICAL ANALYSIS OF 112 CASES OF MYELODYSPLASTIC SYNDROME

The molecular pathogenesis of myelodysplastic syndromes